Wall Street brokerages predict that Endologix, Inc. (NASDAQ:ELGX) will report ($0.64) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Endologix’s earnings, with the lowest EPS estimate coming in at ($0.71) and the highest estimate coming in at ($0.57). Endologix reported earnings per share of ($1.50) in the same quarter last year, which would suggest a positive year over year growth rate of 57.3%. The business is scheduled to report its next quarterly earnings results on Thursday, November 7th.
On average, analysts expect that Endologix will report full year earnings of ($2.73) per share for the current year, with EPS estimates ranging from ($3.02) to ($2.36). For the next year, analysts forecast that the firm will post earnings of ($2.53) per share, with EPS estimates ranging from ($4.47) to ($1.71). Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Endologix.
Endologix (NASDAQ:ELGX) last issued its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.80) by $0.43. Endologix had a negative net margin of 60.32% and a negative return on equity of 120.57%. The business had revenue of $36.24 million during the quarter, compared to analysts’ expectations of $36.09 million.
Endologix stock traded up $0.10 during midday trading on Wednesday, hitting $3.82. The company’s stock had a trading volume of 87,729 shares, compared to its average volume of 230,143. Endologix has a 1-year low of $3.22 and a 1-year high of $16.00. The company has a debt-to-equity ratio of 2.45, a current ratio of 2.53 and a quick ratio of 1.80. The company has a 50-day moving average price of $4.16 and a two-hundred day moving average price of $6.06. The company has a market cap of $63.93 million, a price-to-earnings ratio of -0.53 and a beta of 0.34.
Several large investors have recently modified their holdings of the company. Walleye Trading Advisors LLC acquired a new position in shares of Endologix in the 2nd quarter valued at approximately $158,000. Walleye Trading LLC acquired a new position in shares of Endologix in the 2nd quarter valued at approximately $158,000. Zacks Investment Management acquired a new position in shares of Endologix in the 2nd quarter valued at approximately $108,000. Jane Street Group LLC acquired a new position in shares of Endologix in the 2nd quarter valued at approximately $91,000. Finally, D. E. Shaw & Co. Inc. raised its position in shares of Endologix by 6.9% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 177,931 shares of the medical instruments supplier’s stock valued at $1,288,000 after buying an additional 11,497 shares in the last quarter. Institutional investors own 77.91% of the company’s stock.
Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system.
Featured Article: Accumulation/Distribution
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.